Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Britain Courts Anthropic Amid US Defense Department Dispute 
Apple Turns 50: From Garage Startup to AI Crossroads 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
EMERYVILLE, Calif., Aug. 01, 2017 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report second quarter 2017 financial results on Tuesday, August 8, 2017 after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.
Investor Conference Call and Webcast
The conference call can be accessed by dialing 844-215-3280 for participants in the U.S. or Canada and 484-747-6383 for international callers. The webcast can be accessed live via the investor section of the Adamas website at http://ir.adamaspharma.com/events.cfm and will be available for replay until September 8, 2017.
About Adamas Pharmaceuticals, Inc.
At Adamas, we believe in the power and the promise of medicines derived from a deep understanding of time-dependent biology. Our expertise lies in uncovering and mapping the relationship between disease and drug activity timing patterns. From there, we strive to create medicines with therapeutic profiles that match the pattern of disease to drive a more significant and durable clinical effect. This unique understanding of time-dependent biological processes informs our every innovation, targeting advancement in treatment of chronic neurologic disorders. Our proprietary portfolio includes ADS-5102, a high-dose amantadine therapy taken once-daily at bedtime, in development for the treatment of levodopa-induced dyskinesia in people with Parkinson’s disease, and ADS-4101, a high-dose lacosamide therapy taken once-daily at bedtime, in Phase 1 clinical development for the treatment of partial onset seizures in people with epilepsy. The New Drug Application for ADS-5102 is under review by the U.S. Food and Drug Administration with a PDUFA date of August 24, 2017. Additionally, Adamas’ licensed assets are currently marketed by Allergan under the brand names NAMENDA XR® and NAMZARIC®, and Adamas is eligible to receive royalties on sales of these medicines beginning in June 2018 and May 2020, respectively. For more information, please visit www.adamaspharma.com.
NAMENDA XR® and NAMZARIC® are trademarks of Merz Pharma GmbH & Co. KGaA.
Contact: Ashleigh Barreto Director, Corporate Communications & Investor Relations Adamas Pharmaceuticals, Inc. Phone: 510-450-3567 Email: [email protected]
